Retrospective analysis of medical and pharmacy claims for patients diagnosed with schizophrenia or bipolar disorder in 24 state Medicaid programs.
Kimberly Laubmeier, PhD
Advertisement
Articles by Kimberly Laubmeier, PhD
Advertisement
Latest Updated Articles
- Formulary Restrictions on Atypical Antipsychotics: Impact on Costs for Patients With Schizophrenia and Bipolar Disorder in Medicaid
Published: February 24th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Biktarvy Improves ART Persistence for People With HIV and Mental Health Disorders
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5
